Why is Unicycive Therapeutics, Inc. ?
Unrated Stock - No Analysis Available
Quality key factors
Factor
Value
Sales Growth (5y)
-77.60%
EBIT Growth (5y)
-53.04%
EBIT to Interest (avg)
-28.34
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.71
Sales to Capital Employed (avg)
0.05
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
67.11%
ROCE (avg)
0
ROE (avg)
0
Valuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
8.07
EV to EBIT
-2.32
EV to EBITDA
-2.35
EV to Capital Employed
-9.03
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-315.28%
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Sideways
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Mildly Bullish
Technical Movement
4What is working for the Company
NET PROFIT(HY)
Higher at USD -14.66 MM
RAW MATERIAL COST(Y)
Fallen by 0% (YoY
-5What is not working for the Company
OPERATING CASH FLOW(Y)
Lowest at USD -33.12 MM
ROCE(HY)
Lowest at -3,987.11%
Here's what is working for Unicycive Therapeutics, Inc.
Net Profit
Higher at USD -14.66 MM
than preceding 12 month period ended Jun 2025MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (USD MM)
Raw Material Cost
Fallen by 0% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Unicycive Therapeutics, Inc.
Operating Cash Flow
Lowest at USD -33.12 MM and Fallen
In each year in the last three yearsMOJO Watch
The company's cash revenues from business operations are falling
Operating Cash Flows (USD MM)






